Literature DB >> 29541844

Effects of glycemic control on in-hospital mortality among acute heart failure patients with reduced, mid-range, and preserved ejection fraction.

Kenichi Matsushita1,2, Kazumasa Harada3, Tetsuro Miyazaki3, Takamichi Miyamoto3, Kiyoshi Iida3, Shuzou Tanimoto3, Mayuko Yagawa3, Makoto Takei3, Yuji Nagatomo3, Toru Hosoda3, Hideaki Yoshino3,4, Takeshi Yamamoto3, Ken Nagao3, Morimasa Takayama3.   

Abstract

The relationship between glycemic control and outcome in patients with heart failure (HF) remains contentious. A recent study showed that patients with HF with mid-range ejection fraction (HFmrEF) more frequently had comorbid diabetes relative to other patients. Herein, we examined the association between glycosylated hemoglobin (HbA1c) and in-hospital mortality in acute HF patients with reduced, mid-range, and preserved EF. A multicenter retrospective study was conducted on 5205 consecutive patients with acute HF. Potential risk factors for in-hospital mortality were selected by univariate analyses; then, multivariate Cox regression analysis with backward stepwise selection was performed to identify significant factors. Kaplan-Meier survival curves and log-rank testing were used to compare in-hospital mortality between groups. Across the study cohort, 44% (2288 patients) had reduced EF, 20% had mid-range EF, and 36% had preserved EF. The overall in-hospital mortality rate was 4.6%, with no significant differences among the HF patients with reduced, mid-range, and preserved EF groups. For patients with HFmrEF, higher HbA1c level was a significant risk factor for in-hospital mortality (hazard ratio 1.387; 95% confidence interval 1.014-1.899; P = 0.041). In contrast, HbA1c was not an independent risk factor for in-hospital mortality in HF patients with preserved or reduced EF. In conclusion, HbA1c is an independent risk factor for in-hospital mortality in acute HF patients with mid-range EF, but not in those with preserved or reduced EF. Elucidation of the pathophysiological mechanisms behind these findings could facilitate the development of more effective individualized therapies for acute HF.

Entities:  

Keywords:  Ejection fraction; Glycemia; Glycosylated hemoglobin; Heart failure; Mortality

Mesh:

Substances:

Year:  2018        PMID: 29541844     DOI: 10.1007/s00380-018-1152-2

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  25 in total

1.  Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study.

Authors:  Elizabeth Selvin; Josef Coresh; Sherita H Golden; Frederick L Brancati; Aaron R Folsom; Michael W Steffes
Journal:  Arch Intern Med       Date:  2005-09-12

Review 2.  Advanced glycation end products: sparking the development of diabetic vascular injury.

Authors:  Alison Goldin; Joshua A Beckman; Ann Marie Schmidt; Mark A Creager
Journal:  Circulation       Date:  2006-08-08       Impact factor: 29.690

3.  The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%).

Authors:  Carolyn S P Lam; Scott D Solomon
Journal:  Eur J Heart Fail       Date:  2014-09-11       Impact factor: 15.534

4.  Effect of Heart Failure Secondary to Ischemic Cardiomyopathy on Body Weight and Blood Pressure.

Authors:  Kenichi Matsushita; Kazumasa Harada; Tetsuro Miyazaki; Takamichi Miyamoto; Shun Kohsaka; Kiyoshi Iida; Shuzou Tanimoto; Mayuko Yagawa; Yasuyuki Shiraishi; Hideaki Yoshino; Takeshi Yamamoto; Ken Nagao; Morimasa Takayama
Journal:  Am J Cardiol       Date:  2017-07-31       Impact factor: 2.778

Review 5.  Heart failure with preserved ejection fraction: a clinical dilemma.

Authors:  Michel Komajda; Carolyn S P Lam
Journal:  Eur Heart J       Date:  2014-03-11       Impact factor: 29.983

6.  Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.

Authors:  Richard K Cheng; Margueritte Cox; Megan L Neely; Paul A Heidenreich; Deepak L Bhatt; Zubin J Eapen; Adrian F Hernandez; Javed Butler; Clyde W Yancy; Gregg C Fonarow
Journal:  Am Heart J       Date:  2014-07-22       Impact factor: 4.749

7.  The prognostic significance of atrial fibrillation in heart failure with preserved ejection function: insights from KaRen, a prospective and multicenter study.

Authors:  Christian Bosseau; Erwan Donal; Lars H Lund; Emmanuel Oger; Camilla Hage; Geneviève Mulak; Jean-Claude Daubert; Cecilia Linde
Journal:  Heart Vessels       Date:  2016-12-27       Impact factor: 2.037

Review 8.  Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy.

Authors:  Kalkidan Bishu; Margaret M Redfield
Journal:  Curr Heart Fail Rep       Date:  2013-09

9.  Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction.

Authors:  John R Kapoor; Roger Kapoor; Christine Ju; Paul A Heidenreich; Zubin J Eapen; Adrian F Hernandez; Javed Butler; Clyde W Yancy; Gregg C Fonarow
Journal:  JACC Heart Fail       Date:  2016-06       Impact factor: 12.035

10.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.